Scholarlink

Objective <p>Branched-chain amino acids (BCAA) have been implicated in the risk of cardiovascular disease. However, it is unclear whether dietary BCAA intake, specifically isoleucine, leucine, and valine are associated with coronary artery calcium (CAC) progression.</p> Methods <p>We included the participants from the Coronary Artery Risk Development in Young Adults (CARDIA) study cohort for the analysis. Dietary intake of BCAA was assessed at year 7 of the study. CAC was measured using standardized computed tomography scans at years 15, 20, and 25. CAC progression was defined as follows: for participants with a baseline CAC of 0, progression was defined as CAC &gt; 0 at follow-up; for those with 0 &lt; baseline CAC &lt; 100, progression was defined as an annualized change of ≥ 10; and for those with baseline CAC ≥ 100, progression was defined as an annualized percent change of ≥ 10%. Multivariate adjusted Cox regression models were utilized to examine the associations between BCAA intake and CAC progression.</p> Results <p>Among 2381 included participants (average age 40.4 ± 3.5 years, 44.9% men), 629 participants (26.4%) exhibited CAC progression during a follow-up period of 8.90 ± 2.03 years. In the fully adjusted model, high intake of total BCAA, and its individual components, isoleucine, leucine, and valine were associated with an increased risk of CAC progression by 35.6% (HR, 1.356 [95% CI, 1.040–1.769]), 30.5% (HR, 1.305 [95% CI, 1.001–1.701]), 30.9% (HR, 1.309 [95% CI, 1.003–1.706]), and 33.9% (HR, 1.339 [95% CI, 1.026–1.747]), respectively, compared to their corresponding low intake groups. The associations were consistent across various subgroups, including age, sex, race, and body mass index, but were stronger in participants without baseline CAC (interaction <i>P</i> &lt; 0.001). These results remained robust in a series of sensitivity analyses.</p> Conclusions <p>High dietary intake of BCAA, including isoleucine, leucine, and valine, were independently associated with an increased risk of CAC progression. The findings may implication for dietary modifications in primary prevention of subclinical atherosclerosis.</p> Registration <p>URL: <a href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</a>; Unique identifier: NCT00005130.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dietary branched-chain amino acids intake and coronary artery calcium progression: insights from the coronary artery risk development in young adults (CARDIA) study

  • 期刊论文

  • 发表日期：

    2025年3月19日

查看全文
  • Qing-Yun Hao,
  • Jun Weng,
  • Ting-Ting Zeng,
  • Yu-Hong Zeng,
  • Jing-Bin Guo,
  • Shi-Chao Li,
  • Yi-Ran Chen,
  • Ping-Zhen Yang,
  • Jing-Wei Gao,
  • Ze-Hua Li

摘要

Objective

Branched-chain amino acids (BCAA) have been implicated in the risk of cardiovascular disease. However, it is unclear whether dietary BCAA intake, specifically isoleucine, leucine, and valine are associated with coronary artery calcium (CAC) progression.

Methods

We included the participants from the Coronary Artery Risk Development in Young Adults (CARDIA) study cohort for the analysis. Dietary intake of BCAA was assessed at year 7 of the study. CAC was measured using standardized computed tomography scans at years 15, 20, and 25. CAC progression was defined as follows: for participants with a baseline CAC of 0, progression was defined as CAC > 0 at follow-up; for those with 0 < baseline CAC < 100, progression was defined as an annualized change of ≥ 10; and for those with baseline CAC ≥ 100, progression was defined as an annualized percent change of ≥ 10%. Multivariate adjusted Cox regression models were utilized to examine the associations between BCAA intake and CAC progression.

Results

Among 2381 included participants (average age 40.4 ± 3.5 years, 44.9% men), 629 participants (26.4%) exhibited CAC progression during a follow-up period of 8.90 ± 2.03 years. In the fully adjusted model, high intake of total BCAA, and its individual components, isoleucine, leucine, and valine were associated with an increased risk of CAC progression by 35.6% (HR, 1.356 [95% CI, 1.040–1.769]), 30.5% (HR, 1.305 [95% CI, 1.001–1.701]), 30.9% (HR, 1.309 [95% CI, 1.003–1.706]), and 33.9% (HR, 1.339 [95% CI, 1.026–1.747]), respectively, compared to their corresponding low intake groups. The associations were consistent across various subgroups, including age, sex, race, and body mass index, but were stronger in participants without baseline CAC (interaction P < 0.001). These results remained robust in a series of sensitivity analyses.

Conclusions

High dietary intake of BCAA, including isoleucine, leucine, and valine, were independently associated with an increased risk of CAC progression. The findings may implication for dietary modifications in primary prevention of subclinical atherosclerosis.

Registration

URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005130.

Graphical Abstract